Magazine article Drug Topics

Under Legal Fire, Miles Ends Drug Switch Payments

Magazine article Drug Topics

Under Legal Fire, Miles Ends Drug Switch Payments

Article excerpt

Facing heavy legal pressure, Miles Inc. has agreed to end a program it characterized as reimbursement for the cognitive services of pharmacists in relation to its antihypertensive Adalat CC.

In a settlement reached with the attorneys general of 11 states, Miles agreed to refrain from reimbursement programs such as the one that paid pharmacists $35 for each patient who was switched to Adalat. The company will pay each state $55,000 for their costs, a total of $605,000. Miles will also expunge from its records patient data provided by pharmacists in the Adalat program, which was launched last July and ended Nov. 30.

"This program amounted to a 'bounty' for every customer switched to the Miles drug," said New York State attorney general G. Oliver Koppell in announcing the settlement. "This is a totally unacceptable marketing tactic that turns the pharmacist into a shill for the drug manufacturer instead of being an independent source of objective and professional advice on drug usage."

The program involved contacting more than 11,000 R.Ph.s, and Miles paid out $358,415 to those who participated, Koppell said. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.